clinical trial · NCT05797740
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·—·active not recruiting·n = 367
Multiple SclerosisMavenclad
brief summary
This study aims to describe participants characteristics that can predict the safety and effectiveness of cladribine tablets, as assessed by time-to-discontinuation of treatment with cladribine tablets, and to assess other patient-reported, clinical, and imaging outcomes in participants with relapsing multiple sclerosis (RMS) in the long term, in a real-world setting.
started
Aug 3, 2023
primary completion
Jan 31, 2029
completion
Jan 31, 2029
last updated
Feb 19, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol